Product Overview
Ipamorelin 5 mg by Axiolabs is supplied as a vial labeled with 5 mg of Ipamorelin. Ipamorelin is a synthetic pentapeptide and selective growth-hormone secretagogue investigated for its ability to stimulate pulsatile GH release. It remains an investigational compound rather than an approved GH therapy.
Product Class
Ipamorelin belongs to the growth hormone-releasing peptide (GHRP) family and acts as a ghrelin/growth hormone secretagogue receptor (GHS-R1a) agonist. It is not HGH, an anabolic steroid, SARM or androgen.
Indications
Ipamorelin has no established regulator-approved therapeutic indication. Research has examined growth-hormone secretion and related endocrine physiology. In performance and wellness settings it is discussed for recovery, body composition and GH-related effects, but these uses are not established approved indications.
Mechanism of Action
Ipamorelin activates GHS-R1a receptors in the hypothalamic-pituitary system, promoting endogenous growth-hormone release. Unlike administering recombinant HGH directly, a secretagogue depends on the body's functioning GH axis. Early pharmacologic research characterized Ipamorelin as relatively selective for GH release compared with older GHRPs.
Potential Benefits
Its principal pharmacologic effect is stimulation of endogenous GH secretion, with downstream potential to influence IGF-1 signaling. This explains research interest in recovery, sleep, body composition and tissue metabolism. Evidence for many performance or anti-aging claims remains limited, and Ipamorelin is not directly androgenic or anabolic in the manner of Testosterone.
Synergy & Stacking
CJC-1295 or other GHRH analogues are frequently discussed alongside Ipamorelin because GHRH-receptor and ghrelin-receptor signaling can stimulate GH through complementary pathways. This provides a pharmacologic rationale for research on combined secretagogue signaling, but it does not establish a validated performance protocol.
Sermorelin and Tesamorelin also act through the GHRH receptor and therefore differ mechanistically from Ipamorelin. Combinations with HGH, IGF-1 peptides, Testosterone or anabolic steroids introduce additional endocrine effects and should not be assumed safer or more effective simply because the pathways differ.
HRT/TRT Application
Ipamorelin has no direct role in testosterone replacement therapy. It neither supplies Testosterone nor activates androgen receptors. It also should not be considered equivalent to medically prescribed HGH replacement, since it stimulates endogenous secretion rather than replacing GH directly.
Dosing and Use
The Axiolabs product is labeled as containing 5 mg per vial. There is no FDA-approved Ipamorelin dosing regimen for GH deficiency, anti-aging, bodybuilding or recovery. The 5 mg designation therefore describes stated vial content rather than a recommended injection or treatment schedule.
Female Use
Ipamorelin is non-androgenic and is not expected to produce classical anabolic-steroid virilization such as voice deepening or androgenic hair growth. However, the absence of androgenic activity does not establish reproductive safety, and adequate pregnancy and breastfeeding data are lacking.
Comparative Analysis
Ipamorelin vs CJC-1295: Ipamorelin activates the ghrelin/GHS-R1a receptor, whereas CJC-1295 is a GHRH analogue acting through the GHRH receptor.
Ipamorelin vs Sermorelin: Sermorelin is also GHRH-based, while Ipamorelin belongs to the GHRP/ghrelin-receptor class.
Ipamorelin vs Tesamorelin: Tesamorelin is a GHRH analogue with an established approved pharmaceutical application in specific HIV-associated lipodystrophy settings; Ipamorelin remains investigational.
Ipamorelin vs HGH: HGH directly supplies recombinant growth hormone. Ipamorelin instead stimulates the pituitary to release endogenous GH.
Ipamorelin vs MK-677: Both stimulate GHS-R1a, but Ipamorelin is a peptide whereas Ibutamoren (MK-677) is an orally active non-peptide growth-hormone secretagogue.
Conclusion
Ipamorelin 5 mg by Axiolabs is an investigational GHRP and selective growth-hormone secretagogue associated with endogenous GH signaling. Its GHS-R1a mechanism distinguishes it from GHRH analogues such as CJC-1295, Sermorelin and Tesamorelin, and from direct HGH administration. The stated 5 mg vial strength should not be interpreted as an established therapeutic dose.
Ipamorelin 5mg FAQ
What is Ipamorelin?
Ipamorelin is a synthetic five-amino-acid growth-hormone-releasing peptide that acts primarily through the GHS-R1a receptor.
Is Ipamorelin the same as HGH?
No. HGH directly provides growth hormone, while Ipamorelin stimulates endogenous GH secretion.
Is Ipamorelin a steroid?
No. It is a peptide growth-hormone secretagogue and does not belong to the anabolic-androgenic steroid class.
Why is Ipamorelin combined with CJC-1295?
The compounds target complementary GH-regulatory receptors: Ipamorelin acts through GHS-R1a while CJC-1295 acts through the GHRH receptor. This mechanistic rationale does not constitute an approved combination regimen.
